STAT

Opinion: New drug approval should force the DEA to rethink cannabis-derived medicines

Let's watch the domino effect of the FDA's approval of a medication derived from marijuana.

The Food and Drug Adminstration’s approval of Epidiolex, a medication derived from cannabis, could be life-changing for Americans suffering from certain types of epilepsy. It may also have far-reaching implications for U.S. marijuana policy.

Epidiolex, made by GW Pharmaceuticals, is the first medication derived from the cannabis plant ever approved by the FDA. It has in the past (THC), the active ingredient in marijuana. The FDA’s decision directly contradicts

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Boy Dying In Pfizer Trial; AstraZeneca Yanking Covid Shot, And More
A young boy died in a clinical trial for an experimental Pfizer gene therapy for Duchenne muscular dystrophy, about a year after receiving the therapy.

Related Books & Audiobooks